CN103961486A - Lidocaine compound preparation and aerosol thereof - Google Patents
Lidocaine compound preparation and aerosol thereof Download PDFInfo
- Publication number
- CN103961486A CN103961486A CN201410203125.4A CN201410203125A CN103961486A CN 103961486 A CN103961486 A CN 103961486A CN 201410203125 A CN201410203125 A CN 201410203125A CN 103961486 A CN103961486 A CN 103961486A
- Authority
- CN
- China
- Prior art keywords
- lignocaine
- aerosol
- chitosan
- lidocaine
- compound preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a lidocaine compound preparation, wherein the active component comprises lidocaine. In the compound preparation, an aloe extract and/or chitosan and a rosemary extract as the active components as well as inactive component auxiliary materials are added. Relative to 100 parts by weight of lidocaine, the content of the aloe extract does not exceed 5000 parts by weight, the content of chitosan does not exceed 5000 parts by weight and the content of the rosemary extract does not exceed 200 parts by weight. An aerosol using the lidocaine compound preparation is environment-friendly, stable in physical and chemical properties, good in dispersion and excellent in film-forming property, has the itch-reliving, inflammation-diminishing and sterilizing and self-healing functions, is less in irritation to skins and can be widely applied to infection caused by mild cut, bruise, burn, sunburn and soft tissue injury of skins, mosquito bite, pruritus and miliaria and is used to alleviate symptoms such as local muscular pain, arthralgia and wet.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of slight incised wound, scratch, soft tissue injury that can be used for skin, burn and lignocaine compound preparation and the aerosol thereof of the disease such as mosquito bite, pruritus, miliaria.
Background technology
Mosquito bite is dermatosis in a summer major reason occurred frequently.Owing to containing plurality of antigens composition in the saliva of mosquito or the leachate of poison gland, these antigens are entering after human body skin and can produce atopic reaction with antibody and cause inflammation, make patient occur red, the symptom such as swell, itch, when serious, even produce local bulla, hemorrhagic necrosis etc., to bringing inconvenience our orthobiosis.For mosquito bite, scratch and soft tissue injury, it is generally acknowledged debridement treatment as early as possible, prevention infection occurs.The treatment of doctor trained in Western medicine is to be coated with to spread some antipruritic medicines mostly, Western medicine belongs to corticosteroids medicine mostly, while using these medicines, occur a large amount of more serious bad side reactions as there is local aseptic abscess, erythra, hypotension, feel sick, the untoward reaction such as vomiting, dizzy, hypoglycemia, low blood calcium and hepatic and renal function injure.And the treatment of the traditional Chinese medical science is to smear some Chinese medicinal ointments to carry out heat-clearing and toxic substances removing, subside a swelling and alleviate pain, although patient's centering medical instrument has good Drug tolerance, without anaphylaxiss such as erythra, need the long period just can take effect, can not play the effect of Quick itch stopping.In addition, doctor trained in Western medicine or Chinese traditional treatment all should be noted that to keep wound surface dry, clean, but its embrocate medicine and carry and use all inconveniently, easily produce superinfection, and need repeated multiple times embrocating, there is certain zest.
Lignocaine is the local anesthesia that medical and clinical is conventional, has the antipruritic effect that relieves the pain, and also has report to be used for treating some disease of skin aspect.As Bao Yahua discloses a kind of compound lidocaine emulsifiable paste and preparation method thereof in patent CN101816642A, its effective ingredient is mainly lignocaine and prilocaine, solve the technical problem of existing compound lidocaine emulsifiable paste unstable product quality and clinical practice safety, it is very inconvenient that but this cream products is used, and poor effect.In addition, aerosol is owing to having direct arrival site of action, be evenly distributed, stability rapid-action, medicine is high, wound surface zest is little, dosage control is more accurate, can single dose or the feature such as multiple dose administration, convenience easy to carry and use and be subject to people's favor.Aerosol products is of a great variety, can be divided into following Four types according to the formula of product: (1) active component and propellant.(2) active component, solvent and propellant.(3) active component, surfactant and propellant.(4) active component, solvent, surfactant and propellant.State according to aerosol in tank, aerosol products can be divided into again solvent-borne type aerosol, suspension aerosol and dry-type aerosol.Traditional medicinal aerosol is mainly to adopt freon to make propellant, and it can destroy atmospheric ozone layer.And in CN101756901A, in course of injection, easily form fine particle, and affect the absorption of medicine, cause local drug concentration too high and cause untoward reaction because of the nonunf ormity of drug particles simultaneously.
The people such as Cao Longxiang disclose a kind of lignocaine and have determined aerosol in patent CN101785766B, it has good therapeutic effect for mosquito bite and skin injury, reduce the zest to skin, but this aerosol component is many, contain the components such as lignocaine, chlorhexidine acetate, benzalkonium bromide, PVP-VA64, ethyl acetate, active component is not limited only to lignocaine, and this aerosol does not possess repair to skin simultaneously.
In sum, be Western medicine in the market, and comprise multiple Western medicine active component about Lidocaine Aerosol product main active, aerosol products occurs disperseing inhomogeneous after injection, and product can not film forming, external poor effect.
Summary of the invention
The invention provides that a kind of environmental friendliness, physicochemical properties are stable, good dispersion and there is antipruritic, anti-inflammation and sterilization, self-regeneration function, zest to skin is little, can be widely used in skin slight incised wound, abrade, burn, infection, mosquito bite, pruritus, miliaria that sunburn, soft tissue injury cause and when alleviating the symptoms such as local myalgia, arthralgia, wet disease, can fully be conducive to again the lignocaine compound preparation of preparation of dosage form itself.
Another object of the present invention is as solving in the past many for the external Lida-Mantle Western medicine active component of antipruritic, sterilization, antiinflammation, particularly aerosol products very easily forms fine particle after spraying, disperse inhomogeneous, product does not possess film property or film property is not good, can not promote the problems such as the self-regeneration of skin; Provide one can effectively overcome above problem, and the lignocaine compound type aerosol of good film-forming property.
This technical scheme is lignocaine compound preparation, in described compound preparation, also Aloe extract and/or chitosan and Herba Rosmarini Officinalis extract has not only been added as active component but also as inactive ingredients adjuvant; Relative 100 weight portion lignocaine, the addition of Aloe extract and/or chitosan is no more than 5000 weight portions, and the addition of Herba Rosmarini Officinalis extract is no more than 200 weight portions.
Lignocaine compound preparation of the present invention comprises active component and pharmaceutical adjunct, and its active component comprises lignocaine; In this compound preparation, Aloe extract and/or chitosan were both made to both parts as active component, add as the surfactant in inactive ingredients adjuvant and/or dispersant again, simultaneously, Herba Rosmarini Officinalis extract is both as the part of active component, again as the antioxidant in adjuvant and aromatic.
In the present invention, relative 100 weight portion lignocaine, the addition of Aloe extract is no more than 5000 weight portions, preferably be no more than 1500 weight portions, even more preferably be no more than 1000 weight portions, more preferably 10-1000 weight portion, most preferably 200-1000 weight portion.
In the present invention, relative 100 weight portion lignocaine, the addition of chitosan is no more than 5000 weight portions, is preferably no more than 1500 weight portions, is even more preferably no more than 1000 weight portions, more preferably 10-1000 weight portion; Most preferably 200-1000 weight portion.
Relative 100 weight portion lignocaine, the addition of Herba Rosmarini Officinalis extract is no more than 200 weight portions, is preferably no more than 150 weight portions, is even more preferably no more than 100 weight portions, and preferred content is 20-100 weight portion.
The preferred technical scheme of the present invention is, relative 100 weight portion lignocaine, and the addition of Aloe extract and/or chitosan is no more than 1500 weight portions, and the addition of Herba Rosmarini Officinalis extract is no more than 150 weight portions.
The present invention further preferred technical scheme is, relative 100 weight portion lignocaine meters, and Aloe extract content is 10-1000 weight portion, and chitosan content is 10-1000 weight portion, and Herba Rosmarini Officinalis extract content is 20-100 weight portion.
Described lignocaine is selected from the one in lignocaine, Lidocaine base, lidocaine hydrochloride or lidocaine carbonate.Described Aloe extract comprises one or more in effective ingredient Aloe resin B, aloe-emodin, aloin.
The molecular weight of described chitosan is 200-800.
Described lignocaine compound preparation is Lidocaine Aerosol.
This aerosol also further comprises propellant and solvent.
Described propellant is selected from one or more in isceon, dichlorodifluoromethane, Dichlorotetrafluoromethane, propane, tetrafluoroethane, heptafluoro-propane, normal butane, iso-butane, dimethyl ether.Described solvent is selected from one or more in ethanol, ethyl acetate, propylene glycol.
Addition to described solvent is not particularly limited, as long as can be by various components dissolved.Preparation total amount relatively, its consumption is preferably 0.5-50 % by weight, preferably 1-25 % by weight, more preferably 1-10 % by weight.
In the gross weight of described aerosol, the content of propellant is not less than 50%.
In the gross weight of described aerosol, the content of propellant is 50-99.999 % by weight, preferably 60-99.995 % by weight, and more preferably 70-99.99 % by weight, is preferably 80-99 % by weight.
The optimal technical scheme of aerosol of the present invention is: described propellant is the combination of a kind of and n-propane in isceon, heptafluoro-propane, and its weight proportion is 1:99-99:1, and preferably 10:90-90:10, is preferably 15:85-85:15.
In aerosol of the present invention, further also comprise wetting agent, described wetting agent is selected from one or both in glycerol, propylene glycol, mineral oil, vegetable oil.
Concrete Lidocaine Aerosol formula for a product of the present invention comprises active component, solvent and propellant.The active component of this formula comprises lignocaine, Aloe extract and/or chitosan, Herba Rosmarini Officinalis extract.Wherein the lignocaine in formula plays the effect of antipruritic pain relieving, is one of main active component.Aloe extract plays sterilization, antiinflammatory, reparation and is injured damaged function of organization.Chitosan plays the anti-infection of sterilization and the effect at skin surface film forming and then promotion wound healing.Herba Rosmarini Officinalis plays antioxidation and antiseptical effect.Aloe extract and/or chitosan are except playing the effect of active component, and it has good peptizaiton to lignocaine.In the process of ejecta atomization, lignocaine isoreactivity component is disperseed very even in Aloe extract/chitosan, under the condition without additional dispersant and/or surfactant, can make the aerosol ejecting be uniformly dispersed and easy film forming at skin surface, effectively promote the absorption of medicine.Herba Rosmarini Officinalis extract is except playing the effect of anti-inflammation and sterilization, and it also has antioxidative effect, can effectively ensure Lidocaine Aerosol steady quality.Solvent plays the dissolubility effect that increases active component, promotes each component mix homogeneously.
The preparation method of this Lidocaine Aerosol is first by even to active component and solvent, then its mixture is filtered and is filled in aerosol aluminium pot, and sealing-in aerosol pump, is finally pressed into propellant and get final product.
Except being prepared into Lidocaine Aerosol, the present invention can also add other preparation and pharmaceutically acceptable adjuvant thereof, make and comprise above-mentioned active component lignocaine, and Aloe extract and/or chitosan, Herba Rosmarini Officinalis extract are at other preparation types such as interior spray, water smoke agent, unguentum or suppositorys.Above-mentioned dosage form can prepare by conventional method, and can on the basis of above-mentioned active component, add other additive and auxiliary material.
Compound preparation of the present invention, can be according to the needs of production of compound preparation in the time being prepared into corresponding preparations type, further adds active constituents of medicine acceptable carrier adjuvant of the present invention.Described active constituents of medicine acceptable carrier is selected from other antioxidant, surfactant, dispersant, lubricant, solvent slow release material etc.Conventional carrier comprises cellulose and cellulose derivative, polyvinylpyrrolidone etc.
The present invention is compared with Lida-Mantle of the prior art, and Lida-Mantle of the present invention is Chinese medicine and western medicine compound preparation, and its active component comprises lignocaine, Aloe extract and/or chitosan, Herba Rosmarini Officinalis extract.Wherein, Aloe extract and/or chitosan are both as the part of active component, add as inactive ingredients adjuvant again, conventional surfactant and/or dispersant are substituted, it has good peptizaiton to lignocaine, give the film property function that product is good simultaneously, effectively promoted the absorption of medicine.In addition, Herba Rosmarini Officinalis extract both, as a part for active component, added as inactive ingredients adjuvant again, had substituted conventional antioxidant and aromatic, had strengthened the stability of product.The present invention can, not needing to add on the basis of other surfactant and dispersant, still have stable physicochemical properties.Preparation of the present invention is containing chlorine fluorine alkane not, environmental friendliness.The present invention is different from the different dosage form that the composition of prior art the obtains physicochemical properties of Lida-Mantle by preparation are stable, good dispersion, good film-forming property, there is antipruritic, anti-inflammation and sterilization, self-regeneration function, zest to skin is little, can be widely used in skin slight incised wound, abrade, burn, infection, mosquito bite, pruritus, miliaria that sunburn, soft tissue injury cause and alleviate the symptoms such as local myalgia, arthralgia, wet disease, film property, the dispersibility of the aerosol particularly preparing are good especially, and drug effect is fast.
Detailed description of the invention
Further describe the present invention below in conjunction with embodiment, but the scope of this area is not limited to this.Wherein, because the effect of the preparation of different dosage form is similar, and the preparation method of different preparations is all known, therefore, in an embodiment only taking Lidocaine Aerosol as representative, is used for illustrating the effect that the present invention can obtain.
Embodiment 1
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3g dehydrated alcohol, again this settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, is pressed into 25.25g propellant tetrafluoroethane, obtains stable medicinal aerosol.
Embodiment 2
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3g dehydrated alcohol, again this settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, is pressed into 23.75g propellant tetrafluoroethane, obtains stable medicinal aerosol.
Embodiment 3
The consumption of each component is:
Preparation method: above-mentioned lignocaine, chitosan, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, is pressed into 23.75g propellant tetrafluoroethane, obtains stable medicinal aerosol.
Embodiment 4
The consumption of each component is:
Preparation method: above-mentioned lignocaine, chitosan, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3.00g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, is pressed into 24.75g propellant tetrafluoroethane, obtains stable medicinal aerosol.
Embodiment 5
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, chitosan, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3.00g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, be pressed into 22.25g propellant tetrafluoroethane, obtain stable medicinal aerosol.
Embodiment 6
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, chitosan, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3.00g propylene glycol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, be pressed into 22.25g propellant tetrafluoroethane, obtain stable medicinal aerosol.
Embodiment 7
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, chitosan, Herba Rosmarini Officinalis extract antioxidant through powdered is fully dissolved in 3.00g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, be pressed into 22.25g propellant tetrafluoroethane, obtain stable medicinal aerosol.
Embodiment 8
Preparation method: above-mentioned lignocaine, Aloe extract, chitosan, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3.00g propylene glycol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, is pressed into 22.75g propellant iso-butane, obtains stable medicinal aerosol.
Embodiment 9
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, chitosan, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3.00g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, be pressed into 22.34g propellant tetrafluoroethane, obtain stable medicinal aerosol.
Embodiment 10
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, chitosan, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3.00g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, be pressed into 17.25g propellant tetrafluoroethane, obtain stable medicinal aerosol.
Embodiment 11
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, chitosan, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3.00g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, be pressed into 22.25g propellant heptafluoro-propane, obtain stable medicinal aerosol.
Embodiment 12
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, chitosan, Herba Rosmarini Officinalis extract antioxidant through powdered is fully dissolved in 3.00g propylene glycol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, be pressed into 22.25g propellant heptafluoro-propane, obtain stable medicinal aerosol.
Embodiment 13
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, chitosan, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 2.00g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, be pressed into 24.25g propellant heptafluoro-propane, obtain stable medicinal aerosol.
Embodiment 14
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, chitosan, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3.00g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, be pressed into tetrafluoroethane that total amount is 25.25g and the mixing propellant of dichlorodifluoromethane, obtain stable medicinal aerosol.
Embodiment 15
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, chitosan, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3.00g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, being pressed into total amount is the mixing propellant of tetrafluoroethane/dichlorodifluoromethane of 22.25g, obtains stable medicinal aerosol.
Embodiment 16
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Aloe extract, chitosan, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3.00g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, be pressed into 24.25g propellant heptafluoro-propane, obtain stable medicinal aerosol.
Comparative example 1
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Herba Rosmarini Officinalis extract through powdered is fully dissolved in 3g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, is pressed into 25.25g propellant tetrafluoroethane, obtains medicinal aerosol.
Comparative example 2
The consumption of each component is:
Preparation method: above-mentioned lignocaine, Herba Rosmarini Officinalis extract antioxidant through powdered is fully dissolved in 3g dehydrated alcohol, settled solution is transferred in aerosol aluminium pot, sealing-in aerosol pump, is pressed into 23.75g propellant dichlorodifluoromethane, obtains medicinal aerosol.
The aerosol film property contrast test of embodiment and comparative example
Apart from 10cm place, successively by aerosol spray on clean, dry glass plate, observe the film property of aerosol after spraying, result is as follows:
The contrast of table 1 film property
| Prescription | Film formation time (min) | Film property |
| Embodiment 1 | 5 | Size ratio is compared with homogeneous, thickness homogeneous |
| Embodiment 2 | 5 | Size ratio is compared with homogeneous, thickness homogeneous |
| Embodiment 3 | 5 | Size ratio is compared with homogeneous, thickness homogeneous |
| Embodiment 4 | 5 | Size ratio is compared with homogeneous, thickness homogeneous |
| Embodiment 5 | 4 | Uniform particle diameter, thickness homogeneous |
| Embodiment 6 | 4 | Uniform particle diameter, thickness homogeneous |
| Embodiment 7 | 4 | Uniform particle diameter, thickness homogeneous |
| Embodiment 8 | 3 | Uniform particle diameter, thickness homogeneous |
| Embodiment 9 | 4 | Uniform particle diameter, thickness homogeneous |
| Embodiment 10 | 3 | Uniform particle diameter, thickness homogeneous |
| Embodiment 11 | 5 | Uniform particle diameter, thickness homogeneous |
| Embodiment 12 | 4 | Uniform particle diameter, thickness homogeneous |
| Embodiment 13 | 4 | Uniform particle diameter, thickness homogeneous |
| Embodiment 14 | 4 | Uniform particle diameter, thickness homogeneous |
| Embodiment 15 | 4 | Uniform particle diameter, thickness homogeneous |
| Embodiment 16 | 4 | Uniform particle diameter, thickness homogeneous |
| Comparative example 1 | 6 | Thicker, particle diameter heterogeneity |
| Comparative example 2 | 6 | Very thick, particle diameter heterogeneity |
From table 1, embodiment and comparative example film formation time and film-formation result compare discovery, and the Lidocaine Aerosol that is added with Aloe extract and/or chitosan does not add Aloe extract and/or chitosan has good film property.
When the mass ratio of chitosan and Aloe extract is when certain limit (1.5-3.0), the needed shortest time of aerosol film forming (only needing 3 minutes).
Clinical trial:
The sample of above-mentioned preparation, for clinical patient, is drawn to following experimental result by patient's reaction directly perceived and the observation of skin surface.Wherein, in following course of injection, each metering that uses ejection is 200umL.The aerosol that sprays embodiment 1-16 once after, the skin of mosquito bite reaches antipruritic good result about 15 minutes, there is no pruritus.Slight scald, the skin of scratch is after 24 hours, and skin wound is red and swollen to be eliminated, and color is normal, then after 24 hours, skin heals normally substantially.Be used for alleviating the symptoms such as myalgia, spray above-mentioned sample once after, be onset in 15 minutes.And by observing, the aerosol in embodiment does not have obvious stimulation to skin.When each aerosol that sprays the same comparative example who measures 1,2 preparations, it also has certain antipruritic effect to mosquito bite, but needs multi-injection just can obtain certain remission effect to skin and after 3-6 hour.And during for slight scald, scratch, its healing effect is equally very slow, need to pass through multi-injection.
Claims (10)
1. a lignocaine compound preparation, its active component comprises lignocaine, it is characterized in that, in described compound preparation, also Aloe extract and/or chitosan and Herba Rosmarini Officinalis extract has not only been added as active component but also as inactive ingredients adjuvant; Relative 100 weight portion lignocaine, the addition of Aloe extract and/or chitosan is no more than 5000 weight portions, and the addition of Herba Rosmarini Officinalis extract is no more than 200 weight portions.
2. lignocaine compound preparation according to claim 1, is characterized in that, relative 100 weight portion lignocaine, and the addition of Aloe extract and/or chitosan is no more than 1500 weight portions, and the addition of Herba Rosmarini Officinalis extract is no more than 150 weight portions.
3. lignocaine compound preparation according to claim 1, it is characterized in that, relative 100 weight portion lignocaine meters, Aloe extract content is 10-1000 weight portion, chitosan content is 10-1000 weight portion, and Herba Rosmarini Officinalis extract content is 20-100 weight portion.
4. lignocaine compound preparation according to claim 1, is characterized in that, described lignocaine is selected from the one in lignocaine, Lidocaine base, lidocaine hydrochloride or lidocaine carbonate; Described Aloe extract comprises one or more in effective ingredient Aloe resin B, aloe-emodin, aloin; The molecular weight of described chitosan is 200-800.
5. lignocaine compound preparation according to claim 1, is characterized in that, Aloe extract and/or chitosan are to add as the surfactant in inactive ingredients adjuvant and/or dispersant; Herba Rosmarini Officinalis extract is to add as antioxidant in inactive ingredients adjuvant and aromatic.
6. described in claim 1-5 any one, lignocaine compound preparation is Lidocaine Aerosol.
7. Lidocaine Aerosol according to claim 6, is characterized in that, the mass ratio of chitosan and Aloe extract is 1.5-3.0.
8. Lidocaine Aerosol according to claim 6, is characterized in that, also further comprises propellant and solvent in this aerosol; Described propellant is selected from one or more in isceon, dichlorodifluoromethane, Dichlorotetrafluoromethane, propane, tetrafluoroethane, heptafluoro-propane, normal butane, iso-butane, dimethyl ether; Described solvent is selected from one or more in ethanol, ethyl acetate, propylene glycol; In the gross weight of described aerosol, the content of propellant is not less than 50%.
9. Lidocaine Aerosol according to claim 6, is characterized in that, further comprises wetting agent in this aerosol, and described wetting agent is one or both in glycerol, propylene glycol, mineral oil, vegetable oil.
10. described in claim 1-5 any one, lignocaine compound preparation is spray, water smoke agent, unguentum or suppository.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410203125.4A CN103961486A (en) | 2014-05-14 | 2014-05-14 | Lidocaine compound preparation and aerosol thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410203125.4A CN103961486A (en) | 2014-05-14 | 2014-05-14 | Lidocaine compound preparation and aerosol thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103961486A true CN103961486A (en) | 2014-08-06 |
Family
ID=51231806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410203125.4A Pending CN103961486A (en) | 2014-05-14 | 2014-05-14 | Lidocaine compound preparation and aerosol thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103961486A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740141A (en) * | 2015-04-16 | 2015-07-01 | 广东泰宝医疗科技股份有限公司 | Antibacterialp spray and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101095935A (en) * | 2007-07-12 | 2008-01-02 | 王克强 | Compound recipe aerosol for treating scald |
| CN101785766A (en) * | 2010-01-26 | 2010-07-28 | 江苏天际药业有限公司 | Lidocaine and chlorhexidine aerosol |
-
2014
- 2014-05-14 CN CN201410203125.4A patent/CN103961486A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101095935A (en) * | 2007-07-12 | 2008-01-02 | 王克强 | Compound recipe aerosol for treating scald |
| CN101785766A (en) * | 2010-01-26 | 2010-07-28 | 江苏天际药业有限公司 | Lidocaine and chlorhexidine aerosol |
Non-Patent Citations (3)
| Title |
|---|
| 和承尧编著: "《高原植物资源开发利用研究》", 31 May 2008, 云南科技出版社 * |
| 罗晔等: "壳聚糖在医药领域的应用研究", 《海峡药学》 * |
| 苏振武等主编: "《医院常用药物手册》", 30 June 2011, 军事医学科学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740141A (en) * | 2015-04-16 | 2015-07-01 | 广东泰宝医疗科技股份有限公司 | Antibacterialp spray and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2467759C2 (en) | Composition for local use and its applications | |
| JP2021165312A (en) | Pharmaceutical composition containing loxoprofen | |
| JP6764913B2 (en) | Pharmaceutical composition containing loxoprofen <Reference> | |
| RU2750286C2 (en) | Composition for local application stimulating wound healing | |
| KR100946605B1 (en) | Anti-inflammatory analgesic adhesive patch | |
| CN103191284A (en) | Dragon blood spraying film agent applied to superficial wound and preparation technology thereof | |
| CN105250696A (en) | Traditional Chinese medicine gel capable of promoting skin wound to heal and preparation method of traditional Chinese medicine gel | |
| CN106377519A (en) | Inflammation preventing, disinfecting, heat rash eliminating and itch relieving aerosol and preparation method thereof | |
| JPH01503146A (en) | Methods of treating body tissue and administering medicines to body tissue | |
| CN101342174B (en) | Phthiobuzonum/diclothane compound topical formulation | |
| CN101433544B (en) | External-use pharmaceutical composition formulation with antiphlogistic, swelling-dispersing and analgesic functions, and use | |
| CN108379347A (en) | A kind of hemp floral leaf anti-inflammatory analgetic ointment and preparation method thereof | |
| CN103961486A (en) | Lidocaine compound preparation and aerosol thereof | |
| KR100358819B1 (en) | A patch using crude drugs | |
| CN115381912B (en) | External traditional Chinese medicine compound preparation for reducing cancer pain and preparation method thereof | |
| CN101579423B (en) | Medicament composition for treating beriberi and preparation method thereof | |
| CN110680879A (en) | Traditional Chinese medicine film spraying agent for promoting blood circulation, stopping bleeding, removing necrotic tissue and promoting granulation and preparation method thereof | |
| CN102648922B (en) | Gamuzhuer medicinal latex preparation and preparation method thereof | |
| CN108210462A (en) | The preparation method of a kind of gram of vertical boron sieve local sustained release liposome and application | |
| CN110141653B (en) | Composition containing total gingerol and preparation method thereof | |
| CN101347437B (en) | Medicament composition for treating respiratory disease | |
| CN101468055A (en) | Gel patch for preventing and treating cerebral thrombosis and preparation method thereof | |
| EP4142687B1 (en) | Composition for treating and/or preventing vestibulodynia | |
| CN113713000B (en) | Main medicine component composition for treating sore carbuncle, burn, scald and acne, sustained and controlled release pharmaceutical preparation, and preparation method and application thereof | |
| RU2493837C1 (en) | Anti-inflammatory ointment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 410205 Hunan province Changsha Changsha city high tech Development Zone No. 229 yuan Lu, Hunan Lugu Valley International Medical Equipment Industrial Park B1 building, No. 301 Applicant after: Hunan Xiangyuan Eastern medicine science and Technology Co Ltd Applicant after: Liu Xiaozhong Address before: Quan Lu and Lu Changsha High-tech Development Zone in Hunan province Changsha Lu 410013 Pine Road interchange of agricultural extension venture building 14 Building 1448 room Applicant before: Changsha Meidong Pharmaceutical Technology Co., Ltd. Applicant before: Liu Xiaozhong |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140806 |